Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesVertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc.

PortfolioPortfolio WatchlistWatchlist
Company price
515.7 GBX 2.85 ( 0.56%)
Last update at 2026-10-27T16:40:00Z
VOLUME
107
Market Cap
0.00M
P/E
0.46

Momentum Score

…

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
505.56
Low
524.87
High
52 Week Price Range
362.50
Low
509.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
512.85
Dividend Yield
-
Revenue TTM
12001.30M
Revenue Per Share
46.94
Gross Profit TTM
6440.50M
Debt / Equity
0.21
ROE
22.54%
Net Debt
-1205.30M
ROCE
21.37%
Diluted EPS TTM
9.47

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 4643.20M 248.50M 4379.80M 4232.40M 2730.40M
Net income 3953.20M -535.60M 3619.60M 3322.00M 2342.10M
Selling general administrative - - - - 840.10M
Gross profit 10267.50M 9489.60M 8607.00M 5323.10M 4732.40M
Ebit 4760.70M 280.50M 4423.90M 4378.40M 3892.30M
Ebitda 4967.90M 486.30M 4605.20M 4526.70M 4017.90M
Depreciation and amortization 207.20M 205.80M 181.30M 148.30M 125.60M
Operating income 4760.70M -232.90M 3832.00M 4378.40M 3892.30M
Other operating expenses 7313.90M 11253.00M 6037.20M 4788.10M 4787.40M
Interest expense 13.30M 30.60M 44.10M - 0.00M
Tax provision - - - - 388.30M
Interest income - - - - 56.60M
Income tax expense 690.00M 784.10M 760.20M 910.40M 388.30M
Total revenue 12074.60M 11020.10M 9869.20M 8930.70M 7574.40M
Total operating expenses 5506.80M 9722.50M 4775.00M 1180.50M 1945.40M
Cost of revenue 1807.10M 1530.50M 1262.20M 3607.60M 2842.00M
Total other income expense net -117.50M 481.40M 547.80M -146.00M -1161.90M
Net income applicable to common shares - - - 3322.00M 2342.10M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 26142.80M 22533.20M 22730.20M 18150.90M 13432.50M
Intangible assets 424.20M 825.90M 839.90M 603.60M 400.00M
Other current assets 850.30M 665.70M 623.70M 553.50M 545.80M
Total liab 7477.00M 6123.60M 5149.80M 4238.20M 3332.50M
Total stockholder equity 18665.80M 16409.60M 17580.40M 13912.70M 10100.00M
Other current liab 3144.90M 2691.40M 2829.00M 2438.20M 1947.00M
Common stock 2.50M 2.60M 2.60M 2.60M 2.50M
Retained earnings 13560.00M 9606.80M 10142.40M 6522.80M 3200.80M
Other liab - - - 685.80M 303.30M
Good will 1088.00M 1088.00M 1088.00M 1088.00M 1002.20M
Other assets - - 0.00M 1670.10M 1045.30M
Cash 5087.80M 4569.60M 10369.10M 10504.00M 6795.00M
Total current liabilities 3861.20M 3564.60M 3547.40M 2742.10M 2142.00M
Current deferred revenue 171.80M 206.80M 170.30M - -
Net debt -1205.30M -2820.10M -9560.70M -10504.00M -6795.00M
Short term debt 82.80M 92.30M 83.70M - -
Short long term debt total 3882.50M 1749.50M 808.40M - 556.70M
Other stockholder equity 5119.20M 6672.40M 7449.70M 7387.30M 6896.70M
Property plant equipment - - - 1455.80M 1424.40M
Total current assets 11201.00M 9596.40M 14144.20M 13234.80M 9560.60M
Net tangible assets - - - 12221.10M 8697.80M
Short term investments 1523.30M 1546.30M 849.20M 274.50M 729.90M
Net receivables 2052.80M 1609.40M 1563.40M 1442.20M 1136.80M
Inventory 1686.80M 1205.40M 738.80M 460.60M 353.10M
Accounts payable 461.70M 413.00M 364.90M 303.90M 195.00M
Accumulated other comprehensive income -15.90M 127.80M -14.30M - -
Non currrent assets other 1142.40M 999.30M 895.30M -3246.00M -2826.60M
Non current assets total 14941.80M 12936.80M 8586.00M 3246.00M 2826.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - 179.50M -105.90M
Change to liabilities - - - 120.80M 31.90M
Total cashflows from investing activities -945.40M -3770.00M -3141.70M -321.10M -340.90M
Net borrowings - - - -85.50M -24.40M
Total cash from financing activities -2261.30M -1494.90M -562.20M -67.70M -1478.00M
Change to operating activities - - - 715.00M 230.40M
Net income 3953.20M -535.60M 3619.60M 3322.00M 2342.10M
Change in cash 515.60M -5800.10M -139.70M 3711.90M 811.20M
Begin period cash flow 4572.20M 10372.30M 10512.00M 6800.10M 5988.90M
End period cash flow 5087.80M 4572.20M 10372.30M 10512.00M 6800.10M
Total cash from operating activities 3631.40M -492.60M 3537.30M 4129.90M 2643.50M
Depreciation 207.20M 207.20M 181.30M 148.30M 125.60M
Other cashflows from investing activities -24.70M -241.70M -89.00M - -
Change to inventory -524.20M -517.30M -322.90M -136.40M -92.80M
Change to account receivables -347.30M -99.30M -84.10M -358.60M -274.70M
Sale purchase of stock -2017.40M -1177.10M -427.60M -172.00M -1561.30M
Other cashflows from financing activities -366.20M -398.80M -224.30M 189.80M 130.30M
Change to netincome - - - 318.80M 281.00M
Capital expenditures 437.60M 297.70M 258.40M 204.70M 235.00M
Change in working capital -1199.10M -514.80M -265.70M -495.00M -367.50M
Stock based compensation 685.90M 698.50M 581.20M 491.30M 441.40M
Other non cash items 1180.90M 0.90M -42.60M 663.30M 101.90M
Free cash flow 3193.80M -790.30M 3278.90M 3925.20M 2408.50M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0QZU
Vertex Pharmaceuticals Inc.		 2.85
0.56%		 515.70 0.46 - 9.36 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

50 Northern Avenue, Boston, MA, United States, 02210

617 341 6100

https://www.vrtx.com

6400

Name Title Year Born
Dr. Jeffrey Marc Leiden M.D., Ph.D. Exec. Chairman 1956
Dr. Reshma Kewalramani FASN, M.D. CEO, Pres & Director 1973
Mr. Charles F. Wagner Jr. Exec. VP & CFO 1968
Mr. Stuart A. Arbuckle B.Sc. Exec. VP & COO 1966
Dr. Ourania Tatsis Ph.D. Exec. VP and Chief Regulatory & Quality Officer 1971
Ms. Kristen C. Ambrose Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services 1977
Dr. David M. Altshuler M.D., Ph.D. Exec. VP of Global Research & Chief Scientific Officer 1965
Mr. Mike Tirozzi SVP and Chief Information & Data Officer NA
Susie Lisa Sr. VP of Investor Relations NA
Mr. Damian W. Wilmot Esq. Sr. VP, Chief Risk and Compliance Officer 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…